ALCIDION GROUP LIMITED — Director's Dealing 2017

Apr 12, 2017

==> picture [113 x 35] intentionally omitted <==

13#April#2017#

AustralianSecuritiesExchange Level40,CentralPark 152=158StGeorge'sTerrace PerthWA6000

Appendix#3Y#

PleasefindattachedAppendix3Y,ChangeofDirector’sInterestNoticeforMrLeedman.*

Asannouncedon22March2017,MrLeedmanexercised5,000,000Optionsoverordinary shares in Alcidion Group Limited (“Company”). Following the release of the Company’s QuarterlyCashflowStatement,andincompliancewiththeCompany’ssharetradingpolicy, hehassubsequentlydivestedtheresultingordinaryshares.*

Mr Leedman commented, “Alcidion should be commended on developing a world class Clinical Decision Support Platform and is well positioned to action its commercialisation strategy.TherecentdivestmentoftheAlcidionequitiesisnoreflectiononthepositionofthe Company,butratheritistofreeupsomepersonalfunds.”*

The Company has 607,779,957 ordinary shares on Issue, with over 57% of the shares controlledbyitsfounders,employeesandearlystageinvestors,asdetailedbelow:

Shareholder	Shares	Percentage
ProfessorMalcolmPradhan	134,582,403	22.14%
MrRaymondBlight&MsRobynMorris	97,051,003	15.97%
BSPEMedicalTechnologyPtyLtdATFBSPEMedical TechnologyUnitTrust	84,864,273	13.96%
AllureCapital	19,176,071	3.16%
Employees	11,154,733	1.84%
Others	260,951,474	42.94%

Yoursfaithfully,

RaymondBlight Chief#Executive#Officer#&#Chairman#

ENDS###

info@alcidion.com | www.alcidion.com

40 Greenhill Road | Wayville SA | Australia | ! +61 1800 767 873 | ! +61 8 8271 2644

==> picture [113 x 35] intentionally omitted <==

Forfurtherinformation,pleasecontact: Nathan#Buzza, ExecutiveDirector Ray#Blight, ChiefExecutiveOfficer Ph:+61(0)488862222 Ph:+61(08)82084600 AlcidionGroupLimited AlcidionGroupLimited* nathan.buzza@alcidion.com ray.blight@alcidion.com

About#Alcidion#

AlcidionGroupLimited(ASX: ALC )isapubliclylisted,innovativehealthinformaticscompanythatspecializesin clinicalproductsthatimproveproductivity,safetyandefficiency.Alcidion’ssolutionstargetkeyproblemsfor EmergencyRooms,InpatientServicesandOutpatientDepartmentsandarebuiltuponanextgenerationhealth informaticsplatform,whichincorporatesanintelligentEMR,ClinicalDecisionSupportEngine,DataIntegration Capability,Smartforms,TerminologySupportandStandardsBasedWebServices.*

Alcidion’sfocusisondeliveringsolutionsthatenablehighperformancehealthcareandwhichassistcliniciansby minimisingkeyclinicalrisks,trackingpatientprogressthroughjourneysandimprovingqualityandsafetyof patientcare.*

www.alcidion.com

©AlcidionGroupLimited2017.AlcidionandMiyaareregisteredtrademarks.Allotherbrandsandproduct namesandtrademarksaretheregisteredpropertyoftheirrespectivecompanies.*

info@alcidion.com | www.alcidion.com

40 Greenhill Road | Wayville SA | Australia | ! +61 1800 767 873 | ! +61 8 8271 2644

==> picture [113 x 35] intentionally omitted <==

13 April 2017

Australian Securities Exchange Level 40, Central Park 152-158 St George's Terrace Perth WA 6000

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	BRIAN LEEDMAN
Date of last notice	22/3/2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	DIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	10 APRIL TO 12 APRIL 2017
No. of securities held prior to change	5,000,000 FULLY PAID ORDINARY SHARES 10,000,000 UNLISTED OPTIONS
Class	FULLY PAID ORDINARY SHARES
Number acquired
Number disposed	5,000,000 FULLY PAID ORDINARY SHARES

info@alcidion.com | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 |  +61 8 8271 2644

==> picture [113 x 35] intentionally omitted <==

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$343,859 FOR DISPOSAL OF FULLY PAID ORDINARY SHARES
No. of securities held after change	10,000,000 UNLISTED OPTIONS - 5,000,000 @ $0.06 exercisable after release of Appendix 4E for financial year ending 30 June 2017 - 5,000,000 @ $0.08 exercisable after release of Appendix 4E for financial year ending 30 June 2018 All 10,000,000 unlisted options have an option exercise expiry date of 30 June 2020
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	ON-MARKET TRADES

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 278] intentionally omitted <==

----- Start of picture text -----

Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for
a contract in relation to which the
interest has changed
Interest acquired
Interest disposed
----- End of picture text -----

info@alcidion.com | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 |  +61 8 8271 2644

==> picture [113 x 35] intentionally omitted <==

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

art 3 – +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

### ENDS ###

For further information, please contact:

Duncan Craig

Chief Financial Officer and Company Secretary Ph: +61 (08) 8208 4600 Alcidion Corporation duncan.craig@alcidion.com

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion’s solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion’s focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies

info@alcidion.com | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 |  +61 8 8271 2644